www.fdanews.com/articles/142276-regeneron-8217-s-arcalyst-gout-drug-gets-july-pdufa-target
Regeneron’s Arcalyst Gout Drug Gets July PDUFA Target
December 7, 2011
The FDA has set a July 30, 2012, user fee action goal date to review Regeneron’s sBLA for interleukin-1 inhibitor Arcalyst to treat gout flare-ups.
Washington Drug Letter
Washington Drug Letter